Earnings
Home›Earnings›Previews›Benzinga highlights biotech stocks including AbbVie an…
Benzinga highlights biotech stocks including AbbVie and Immix Biopharma
The biotech list points to AbbVie’s reliance on Humira, plus the company’s acquisition of Allergan, while Immix Biopharma is described as a clinical stage oncology and inflammation drug developer.
Benzinga published a curated set of biotech stock ideas, framing the group as a way to diversify exposure to the sector amid ongoing efforts to develop vaccines and boosters.
The selection includes AbbVie, which the outlet describes as having major exposure to immunology and oncology, with Humira cited as accounting for close to half of the company’s current profits.
Benzinga also notes that AbbVie was spun off from Abbott in early 2013 and that its recent acquisition of Allergan adds drugs in areas including aesthetics and women’s health.
Another name on the list is Immix Biopharma, which Benzinga characterizes as a clinical stage biopharmaceutical company developing tissue specific therapeutics in oncology and inflammation.